{
  "id": 7175077,
  "title": "Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer",
  "url": "https://urgent.news/2026/09/13/significant-survival-boost-with-novel-adcs-in-relapsed-small-cell",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-13T20:45:00.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/iaslc/122982"
  },
  "original_language": "en",
  "account": null,
  "summary": "Two investigational anti-B7-H3 antibody-drug conjugates (ADCs) have shown significant survival benefits in patients with relapsed small-cell lung cancer (SCLC). According to Medical Xpress, the ARTEMIS-008 trial found that risvutatug rezetecan (Ris-Rez) improved overall survival compared to topotecan in patients whose disease progressed after platinum-based chemotherapy.\n\nThe trial involved 461 patients in China who were randomly assigned to receive either Ris-Rez or topotecan. At a median follow-up of 12.2 months, the median overall survival was 18.5 months with Ris-Rez and 10.3 months with topotecan. Ris-Rez reduced the risk of death by 54%.\n\nMedPage Today also reported on a pair of Chinese trials, including the TAISHAN-302 study, which found that two investigational ADCs improved survival outcomes in patients with relapsed SCLC. However, further details of this study were not provided.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer",
        "url": "https://urgent.news/2026/09/13/tam-peli-extends-survival-by-nearly-four-months-in-relapsed-small",
        "published": "2026-09-13T01:50:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}